1Global Alliance for TB Drug Development. Scientific blueprint for tuberculosis drug development [J]. Tuberculosis, 2001,81 (Suppl 1 ): 1
2Igarashi M, Nakagawa N, Hattori S, et al. Caprazamycin A-F, novel anti-TB antibiotics from Streptomyces sp.[C]. Abstracts 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, ASM. Washigton,D.C. 2002:232
3Payne D J, Warren P V, Holmes D J, et al. Bacterial fatty acid biosynthesis: a genomics-driven taget for drug discovery [J]. Drug Discovery Today,2001,6: 537
4Editors. Advances in TB drug development [J]. Scrip,2002,No. 2717:20
5Igarashi M, Nakamura H, Nakanawa H, et al. Tubelactomicin A, a novel 16-memberd lactone antibiotic from Nocardia sp. [J]. J Antibiot, 2000,53: 1096,1102
6Stover C K, Warrener P, van Devanter D R, et al. A small-molecule nitromidazopyran drug candidate for treatment of tuberculosis [J]. Nature, 2000,405: 962
7Biva M, Fioravanti R, Porretta G C, et al. Synthesis and microbialogical activityt of pyrrole analogs of BM-212, a potent antitubercular agent [J]. Med Chem Res, 1999,9:19
8Parrish N M, Houston T, Jones P B, et al. In vitro activity of a novel antimycobacterial compound, N-octanesulfonylacetamide, and its effects on lipid and mycolic acid synthesis [J]. Antimicrob Agents Chemother, 2001, 45:1143
9Ishikaw T, Benzo C. Phenathridine bases and their antibacterial activity [J]. Med Chem Rev, 2001,21: 61
